Ann: ePAT Signs MOU with UK Insurance Counter-Fraud Group-MNQ.AX, page-65

"like comparing every junior gold company to one who has made it"

ResApp have far from "made it" - They have zero in revenue, not one FDA submission and only half their clinical studies complete.

I invested in RAP at the ground floor a very similar position to where MNQ is today - I will go as far as saying MNQ is in a stronger position than when ResApp relisted. MNQ already has existing partners, Australian clinical results and a prototype working application - I dont remember RAP having such a strong foundation to launch from.

Dont get me wrong, ResApp has enormous potential and a wide market which is why the company is valued north of $250M, to me ResApp is still undervalued which is why the MNQ story has so much upside.

The people who bought MNQ in the 2c area have already bailed, these roadshows will bring on fresh investors and with such a light market cap it wont take much to see this move north again.